Jun 23, 2020 / 07:00PM GMT
George Farmer - BMO Capital Markets Equity Research - Analyst
Hi. Good afternoon. I'm George Farmer, senior biotechnology analyst at BMO Capital Markets. Thank you for attending our afternoon session today, our Virtual BMO Healthcare Conference.
With me today, I'm very pleased to have Stéphane Bancel, the Chief Executive Officer of Moderna, to speak with us in a fireside chat format. We'll talk about Moderna's very exciting RNA therapeutic vaccine pipeline with, I think, most focus on 1273, the coronavirus vaccine that is currently in Phase II development, and as we all understand, is about to begin Phase III. So thank you, Stéphane, for being here.
Stéphane Bancel - Moderna, Inc. - CEO & Director
Thank you for having me, George.
Questions and Answers:
George Farmer - BMO Capital Markets Equity Research - AnalystYes. Very good. So perhaps you can just give us an overview, for maybe people who aren't entirely familiar with what Moderna is doing, about the overall Moderna
Trustpilot
